CN102066417B - 提纯凝固因子viii的方法 - Google Patents

提纯凝固因子viii的方法 Download PDF

Info

Publication number
CN102066417B
CN102066417B CN200980123974.6A CN200980123974A CN102066417B CN 102066417 B CN102066417 B CN 102066417B CN 200980123974 A CN200980123974 A CN 200980123974A CN 102066417 B CN102066417 B CN 102066417B
Authority
CN
China
Prior art keywords
fviii
resin
purification
protein
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980123974.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102066417A (zh
Inventor
卡里恩·博里瓦尔
乌尔里卡·埃里克松
古斯塔夫·吉尔加姆
麦特斯·耶恩贝里
斯特凡·温厄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octapharma AG
Original Assignee
Octapharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40076764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102066417(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma AG filed Critical Octapharma AG
Publication of CN102066417A publication Critical patent/CN102066417A/zh
Application granted granted Critical
Publication of CN102066417B publication Critical patent/CN102066417B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
CN200980123974.6A 2008-06-24 2009-06-24 提纯凝固因子viii的方法 Active CN102066417B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12940208P 2008-06-24 2008-06-24
EP08158893.1 2008-06-24
EP08158893 2008-06-24
US61/129,402 2008-06-24
PCT/EP2009/057883 WO2009156430A1 (en) 2008-06-24 2009-06-24 A process of purifying coagulation factor viii

Publications (2)

Publication Number Publication Date
CN102066417A CN102066417A (zh) 2011-05-18
CN102066417B true CN102066417B (zh) 2015-11-25

Family

ID=40076764

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980123974.6A Active CN102066417B (zh) 2008-06-24 2009-06-24 提纯凝固因子viii的方法

Country Status (19)

Country Link
US (1) US8329871B2 (https=)
EP (2) EP2300497B1 (https=)
JP (1) JP5619738B2 (https=)
KR (3) KR20160104740A (https=)
CN (1) CN102066417B (https=)
AU (1) AU2009264282B2 (https=)
BR (1) BRPI0914695B1 (https=)
CA (1) CA2728047C (https=)
DK (2) DK2300497T3 (https=)
ES (2) ES2391613T3 (https=)
IL (3) IL229583B (https=)
MX (1) MX2010013908A (https=)
PL (1) PL2300497T3 (https=)
PT (1) PT2300497E (https=)
RU (2) RU2698392C2 (https=)
SI (1) SI2300497T1 (https=)
UA (1) UA100901C2 (https=)
WO (1) WO2009156430A1 (https=)
ZA (1) ZA201009162B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399620B2 (en) 2007-07-11 2013-03-19 Novo Nordisk A/S Purification of factor VIII using a mixed-mode or multimodal resin
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
CN102119172A (zh) 2008-08-21 2011-07-06 奥克塔法马股份有限公司 重组制备的人类因子viii和ix
US20110178019A1 (en) * 2008-09-03 2011-07-21 Brita Rippner New protecting compositions for recombinantly produced factor viii
US20110166332A1 (en) * 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
DK2552948T3 (en) * 2010-03-30 2016-10-17 Octapharma Ag A process for the purification of the protein growth factor G-CSF
EP2553095B1 (en) * 2010-03-30 2016-10-12 Octapharma AG A process for purifying vitamin K dependent proteins such as coagulation factor IX
AU2011244348B2 (en) 2010-04-20 2015-02-12 Octapharma Ag New stabilizing agent for pharmaceutical proteins
WO2012049285A1 (en) 2010-10-14 2012-04-19 Octapharma Ag A method for the quantitative glycosylation analysis of proteins
RU2591523C2 (ru) * 2010-11-05 2016-07-20 Ф. Хоффманн-Ля Рош Аг Оптимизированный метод захвата антител хроматографией смешанного типа
RU2600886C2 (ru) * 2011-05-13 2016-10-27 Октафарма Аг Способ повышения продуктивности эукариотических клеток в продуцировании рекомбинантного fviii
JP5640189B2 (ja) 2011-06-17 2014-12-17 学校法人東日本学園 ループスアンチコアグラント検出用血液凝固時間の測定方法
US20130109807A1 (en) * 2011-10-26 2013-05-02 Bio-Rad Laboratories, Inc. Removal of virucidal agents in mixed mode chromatography
US20150275195A1 (en) * 2012-10-24 2015-10-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
CN103880947B (zh) * 2012-12-21 2016-01-13 武汉禾元生物科技股份有限公司 一种分离纯化高纯度重组人血清白蛋白的层析方法
SG10201709131UA (en) * 2013-03-08 2017-12-28 Genzyme Corp Continuous purification of therapeutic proteins
EP3008085A4 (en) * 2013-06-13 2017-05-10 Biogen MA Inc. Anti-factor viii antibodies or uses thereof
WO2015005960A1 (en) 2013-07-12 2015-01-15 Emd Millipore Corporation Removal of fragments from a sample containing a target protein using activated carbon
WO2015021423A2 (en) * 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
MY173548A (en) 2013-09-24 2020-02-04 Pfizer Fxa variant compositions
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI671312B (zh) * 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
RU2695428C2 (ru) * 2014-01-20 2019-07-23 Октафарма Аг СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag
EP3097188B1 (en) * 2014-01-24 2018-08-29 AM-Pharma B.V. Downstream processing of an alkaline phosphatase
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
CN104861060A (zh) * 2014-02-21 2015-08-26 神州细胞工程有限公司 一种纯化凝血因子viii的方法
KR20170010750A (ko) 2014-05-29 2017-02-01 에이전시 포 사이언스, 테크놀로지 앤드 리서치 단백질 추출 방법들
US10626164B2 (en) * 2014-07-25 2020-04-21 Csl Limited Purification of VWF
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506117D0 (en) * 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
WO2016207328A1 (en) * 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
EP3205665A1 (en) 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
GB201617240D0 (en) * 2016-10-11 2016-11-23 Profactor Pharma Ltd Purification process
EP3642225A1 (en) * 2017-06-23 2020-04-29 Baxalta Incorporated Purification of factor viii subspecies
CN107226859B (zh) * 2017-08-10 2020-11-24 博雅生物制药集团股份有限公司 一种人凝血因子ⅷ的制备方法
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
HK40046210A (en) 2018-08-31 2021-10-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
TWI787710B (zh) * 2020-01-20 2022-12-21 中國大陸商上海藥明生物技術有限公司 用於親和層析的新型清洗緩衝液
CN118217951B (zh) * 2024-04-01 2025-05-23 山东建筑大学 一种水中的高纯度磷回收装置和方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008686A1 (en) * 1992-10-21 1994-04-28 Cornell Research Foundation, Inc. Multimodal chromatographic separation media and process for usingsame
CN1134157A (zh) * 1993-11-04 1996-10-23 奥克塔法马有限公司 一种通过层析法制备含因子viii的病毒灭活级分的方法
CN1538973A (zh) * 2001-07-13 2004-10-20 因子viii的分离
WO2005082483A1 (en) * 2004-02-27 2005-09-09 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
WO2005121163A2 (en) * 2004-06-07 2005-12-22 Upfront Chromatography A/S Isolation of plasma or serum proteins
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
EP0711485B1 (en) 1993-06-11 1997-04-16 Nortel Networks Corporation Method for providing user controlled call management services
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
FR2887883B1 (fr) * 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20080125580A1 (en) * 2006-07-14 2008-05-29 Genentech, Inc. Refolding of Recombinant Proteins
RU2324495C1 (ru) * 2006-08-31 2008-05-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения препарата фактора свертывания viii крови человека
CA2674881A1 (en) * 2007-02-01 2008-08-07 Baxter International Inc. Fviii-independent fix-mutant proteins for hemophilia a treatment
ES2392569T3 (es) * 2007-06-13 2012-12-11 Csl Behring Gmbh Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
US8399620B2 (en) 2007-07-11 2013-03-19 Novo Nordisk A/S Purification of factor VIII using a mixed-mode or multimodal resin
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008686A1 (en) * 1992-10-21 1994-04-28 Cornell Research Foundation, Inc. Multimodal chromatographic separation media and process for usingsame
CN1134157A (zh) * 1993-11-04 1996-10-23 奥克塔法马有限公司 一种通过层析法制备含因子viii的病毒灭活级分的方法
CN1538973A (zh) * 2001-07-13 2004-10-20 因子viii的分离
WO2005082483A1 (en) * 2004-02-27 2005-09-09 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
WO2005121163A2 (en) * 2004-06-07 2005-12-22 Upfront Chromatography A/S Isolation of plasma or serum proteins
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins

Also Published As

Publication number Publication date
ES2538706T3 (es) 2015-06-23
EP2300497B1 (en) 2012-08-08
AU2009264282A1 (en) 2009-12-30
EP2537862B1 (en) 2015-03-18
ES2391613T3 (es) 2012-11-28
BRPI0914695B1 (pt) 2022-04-19
IL209758A (en) 2014-02-27
BRPI0914695A2 (pt) 2015-10-20
IL229583B (en) 2018-03-29
SI2300497T1 (sl) 2013-02-28
KR20170102065A (ko) 2017-09-06
KR20110038634A (ko) 2011-04-14
RU2567811C2 (ru) 2015-11-10
CA2728047C (en) 2019-07-30
RU2015141849A3 (https=) 2018-12-28
UA100901C2 (ru) 2013-02-11
PT2300497E (pt) 2012-10-30
RU2015141849A (ru) 2018-12-28
CA2728047A1 (en) 2009-12-30
JP5619738B2 (ja) 2014-11-05
JP2011525523A (ja) 2011-09-22
KR20160104740A (ko) 2016-09-05
CN102066417A (zh) 2011-05-18
EP2537862A1 (en) 2012-12-26
PL2300497T3 (pl) 2013-02-28
RU2011102437A (ru) 2012-07-27
IL209758A0 (en) 2011-02-28
DK2537862T3 (en) 2015-06-15
IL229583A0 (en) 2014-01-30
RU2698392C2 (ru) 2019-08-26
ZA201009162B (en) 2011-10-26
US8329871B2 (en) 2012-12-11
US20110160435A1 (en) 2011-06-30
MX2010013908A (es) 2011-01-21
AU2009264282B2 (en) 2013-04-18
DK2300497T3 (da) 2012-10-29
WO2009156430A1 (en) 2009-12-30
EP2300497A1 (en) 2011-03-30
KR101804136B1 (ko) 2017-12-04
KR101700722B1 (ko) 2017-01-31

Similar Documents

Publication Publication Date Title
CN102066417B (zh) 提纯凝固因子viii的方法
JP5323072B2 (ja) 混合方式又は多様式樹脂を使用する第ｖｉｉｉ因子の精製
CN102858971B (zh) 纯化维生素k依赖性蛋白如凝血因子ix的方法
JP2021004265A (ja) 組換えａｄａｍｔｓ１３および他のタンパク質を精製する方法ならびにそれらの組成物
ES2552337T3 (es) Procedimientos para la preparación de plasminógeno
CN103025757A (zh) 二价阳离子结合蛋白在阴离子交换树脂上的纯化方法
JP2017509593A (ja) ＦＶＩＩＩ：Ｃ／ＦＶＩＩＩ：Ａｇの改良された比を有する第ＶＩＩＩ因子を製造するための方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant